Recursion Exscientia full stack competitor

The real competitive threat is not just another drug design model, it is a company that already stitched data generation, chemistry, and clinical execution into one machine. Recursion became that after closing Exscientia on November 20, 2024, combining Recursion’s image based biology engine with Exscientia’s medicinal chemistry and development stack. That matters because pharma buyers can hand one partner a program from target hypothesis through lead optimization and into the clinic, instead of buying separate tools from separate vendors.

• Recursion’s core data advantage starts upstream of structure prediction. It runs large scale perturbation experiments and cell imaging to build phenomaps, then layers in patient data from Tempus for oncology. That gives it a way to ask which genes, pathways, and patient subgroups matter before choosing which molecule to design.
  3 recursion 5 recursion 6 tempus
• The Exscientia combination filled in Recursion’s weakest flank, chemistry. Exscientia brought precision chemistry and a deeper path from hit finding to candidate design, while Recursion brought automated wet labs and phenomics. The merged company also disclosed more than 10 clinical and preclinical programs and more than 10 partnered programs, which is unusual scale for an AI native biotech platform.
  1 recursion 2 recursion 4 sacra
• The competition also reaches down into infrastructure. Recursion helped release Boltz-2 as an open source structure and binding affinity model, which pushes structural biology capability into the public domain. That makes the market less about owning one model and more about owning proprietary data, lab throughput, and actual drug programs.
  7 recursion 8 boltz

Going forward, this market is likely to split between full stack AI biotechs and narrower model vendors. Recursion is pushing toward the full stack end, while Isomorphic is strongest where structure prediction and molecular design are the bottleneck. The companies that win the most budget will be the ones that can turn proprietary data into molecules, and molecules into clinical proof.